Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Leirisalo-Repo

Showing results (231-240 of 251) with videos related to

Pageof 26
Sort By:
Scandinavian Journal of Rheumatology|September 2, 2015
Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trialL Kuusalo, K Puolakka, H Kautiainen, et al.
Annals of the Rheumatic Diseases|April 17, 2001
Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritisJ M Albers, L Paimela, P Kurki, et al.
Clinical and Experimental Rheumatology|March 30, 2010
Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo TrialK L Karstila, V M Rantalaiho, J T Mustonen, et al.
Clinical and Experimental Rheumatology|January 9, 2007
Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritisS Laivoranta-Nyman, T Möttönen, P Hannonen, et al.
Annals of the Rheumatic Diseases|August 17, 2004
Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled studyT K Kvien, J S H Gaston, T Bardin, et al.
Annals of the Rheumatic Diseases|May 15, 2002
Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertensionT K Kvien, H K Zeidler, P Hannonen, et al.
Annals of the Rheumatic Diseases|October 10, 2009
Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesionsF Van den Bosch, B Manger, P Goupille, et al.
Genes and Immunity|August 19, 2005
Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritisM F Seldin, R Shigeta, K Laiho, et al.
British Journal of Rheumatology|September 12, 1998
Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral goldH K Zeidler, T K Kvien, P Hannonen, et al.
Annals of the Rheumatic Diseases|September 4, 2004
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitisA Calin, B A C Dijkmans, P Emery, et al.
Pageof 26

Showing results (231-240 of 251) with videos related to

Sort By:
Pageof 26
Scandinavian Journal of Rheumatology|September 2, 2015
Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trialL Kuusalo, K Puolakka, H Kautiainen, et al.
Annals of the Rheumatic Diseases|April 17, 2001
Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritisJ M Albers, L Paimela, P Kurki, et al.
Clinical and Experimental Rheumatology|March 30, 2010
Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo TrialK L Karstila, V M Rantalaiho, J T Mustonen, et al.
Clinical and Experimental Rheumatology|January 9, 2007
Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritisS Laivoranta-Nyman, T Möttönen, P Hannonen, et al.
Annals of the Rheumatic Diseases|August 17, 2004
Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled studyT K Kvien, J S H Gaston, T Bardin, et al.
Annals of the Rheumatic Diseases|May 15, 2002
Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertensionT K Kvien, H K Zeidler, P Hannonen, et al.
Annals of the Rheumatic Diseases|October 10, 2009
Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesionsF Van den Bosch, B Manger, P Goupille, et al.
Genes and Immunity|August 19, 2005
Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritisM F Seldin, R Shigeta, K Laiho, et al.
British Journal of Rheumatology|September 12, 1998
Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral goldH K Zeidler, T K Kvien, P Hannonen, et al.
Annals of the Rheumatic Diseases|September 4, 2004
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitisA Calin, B A C Dijkmans, P Emery, et al.
Pageof 26